exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47 .18 Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride  monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473–81. 19 Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M.  The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195–202. 20 World Medical Association Declaration of Helsinki.  Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925–26. 21 Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the  joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–52. 22 Anderson RT , G